XML 17 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 1,782 $ 963
Trade receivables 5,822 7,128
Inventories 4,731 4,924
Prepaid expenses 899 1,100
Other current assets 468 701
Assets held for sale 92 566
Total current assets 13,794 15,382
Deferred income taxes 368 574
Other non-current assets 731 932
Property, plant and equipment, net 6,868 7,673
Identifiable intangible assets, net 14,005 17,640
Goodwill 24,917 28,414
Total assets 60,683 70,615
Current liabilities:    
Short-term debt 2,216 3,646
Sales reserves and allowances 6,711 7,881
Trade payables 1,853 2,069
Employee-related obligations 870 549
Accrued expenses 1,868 3,014
Other current liabilities 804 724
Liabilities held for sale   38
Total current liabilities 14,322 17,921
Long-term liabilities:    
Deferred income taxes 2,140 3,277
Other taxes and long-term liabilities 1,727 1,843
Senior notes and loans 26,700 28,829
Total long-term liabilities 30,567 33,949
Commitments and contingencies, see note 13
Total liabilities 44,889 51,870
Teva shareholders' equity:    
Preferred shares of NIS 0.10 par value per mandatory convertible preferred share; December 31, 2018: no shares authorized or issued; December 31, 2017: authorized 5.0 million shares; issued 3.7 million shares   3,631
Ordinary shares of NIS 0.10 par value per share; December 31, 2018 and December 31, 2017: authorized 2,495 million shares; issued 1,196 million shares and 1,124 million shares, respectively 56 54
Additional paid-incapital 27,210 23,479
Accumulated deficit (5,958) (3,803)
Accumulated other comprehensive loss (2,459) (1,853)
Treasury shares as of December 31, 2018 and December 31, 2017: 106 million ordinary shares and 107 million ordinary shares, respectively (4,142) (4,149)
Stockholders' equity attributable to Teva shareholders 14,707 17,359
Non-controlling interests 1,087 1,386
Total equity 15,794 18,745
Total liabilities and equity $ 60,683 $ 70,615